FY2025 EPS Estimates for Vericel Reduced by HC Wainwright

Vericel Co. (NASDAQ:VCEL) – Equities research analysts at HC Wainwright lowered their FY2025 earnings per share estimates for shares of Vericel in a report released on Friday, February 28th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn $0.26 per share for the year, down from their previous estimate of $0.35. HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.14 per share. HC Wainwright also issued estimates for Vericel’s FY2027 earnings at $1.18 EPS, FY2028 earnings at $1.93 EPS and FY2029 earnings at $2.66 EPS.

Several other research firms have also commented on VCEL. StockNews.com lowered Vericel from a “hold” rating to a “sell” rating in a research report on Friday, February 28th. BTIG Research increased their target price on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Stephens reiterated an “overweight” rating and set a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. Canaccord Genuity Group increased their target price on Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Finally, Truist Financial reiterated a “buy” rating and set a $61.00 target price (down previously from $67.00) on shares of Vericel in a research report on Monday. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Vericel currently has a consensus rating of “Moderate Buy” and an average target price of $62.29.

Vericel Trading Up 3.3 %

Vericel stock opened at $51.14 on Monday. Vericel has a 12 month low of $39.12 and a 12 month high of $63.00. The stock’s 50 day simple moving average is $56.93 and its two-hundred day simple moving average is $51.93. The firm has a market cap of $2.52 billion, a PE ratio of 852.48 and a beta of 1.72.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VCEL. Meeder Asset Management Inc. increased its stake in shares of Vericel by 8.4% in the 4th quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 183 shares during the last quarter. Atria Investments Inc increased its stake in shares of Vericel by 2.4% in the 4th quarter. Atria Investments Inc now owns 7,952 shares of the biotechnology company’s stock worth $437,000 after acquiring an additional 184 shares during the last quarter. Captrust Financial Advisors increased its stake in shares of Vericel by 3.4% in the 4th quarter. Captrust Financial Advisors now owns 6,111 shares of the biotechnology company’s stock worth $336,000 after acquiring an additional 199 shares during the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Vericel by 0.8% in the 4th quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company’s stock worth $1,312,000 after acquiring an additional 200 shares during the last quarter. Finally, Avantax Advisory Services Inc. increased its stake in shares of Vericel by 1.7% in the 4th quarter. Avantax Advisory Services Inc. now owns 13,803 shares of the biotechnology company’s stock worth $758,000 after acquiring an additional 234 shares during the last quarter.

Insider Buying and Selling at Vericel

In other Vericel news, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the transaction, the director now owns 26,595 shares in the company, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jonathan Siegal sold 1,092 shares of the firm’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total value of $67,693.08. Following the completion of the transaction, the insider now owns 1,206 shares in the company, valued at $74,759.94. The trade was a 47.52 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,500 shares of company stock worth $466,200. Corporate insiders own 5.20% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.